Global End-Stage Renal Disease Market Extends at a Healthy CAGR of 13.9% by 2030

Introduction

Global End-Stage Renal Disease Market Grows at a Staggering CAGR of 13.9%

Chronic kidney disease, which impairs the function of the kidneys, is associated with end-stage renal diseases. A patient with the end-stage renal disease does not have optimal kidney function. The kidney excretes urine, which assists in the elimination of wastes and excess fluids. Any condition that reduces kidney function results in chronic kidney disease, which can progress to end-stage renal disease (ESRD), in which the kidneys cannot function independently. Also referred to as kidney failure. In the elderly population, hypertension, diabetes, and smoking all contribute to the development of end-stage renal disease. The most prevalent cause of ESRD is diabetes, while hypertension (high blood pressure) is the second most prevalent cause. ESRD/CKD is treated with kidney transplantation or dialysis to ensure survival.

Market Dynamics

Growing Number of Patients with hypertension and Diabetes and the Rising Prevalence of Chronic Kidney Disease Drives the Global Market

A growing patient population affected by diabetes and hypertension contributes to the global market expansion. Approximately one-third of people with diabetes develop chronic kidney disease (CKD) due to this condition. Persistent blood pressure is the primary cause of hypertension, which increases the risk of end-stage renal disease (ESRD). The leading cause of advanced kidney disease is diabetes, while hypertension is the second most common cause. Consequently, the number of patients suffering from hypertension and diabetes is increasing, which is the primary factor driving the market growth.

In response to the rising incidence of renal failure in developed and developing nations, technologically advanced products have been developed. This innovation aims to provide satisfactory and effective results for patients with kidney failure. Thus, technological advances in treating renal failure contribute to the market's expansion.

Regional Analysis

Asia-Pacific holds the largest share of the ESRD market. This is explained by rising healthcare costs, expanding government programs, campaigns to raise awareness of chronic kidney disease (CKD), technologically advanced products, and the presence of recently built, cutting-edge healthcare facilities in the area. Due to factors like lifestyle stress, a sizable population base, improving diagnosis quality, and rising patient affordability, the Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period.

Key Highlights

• The global end-stage renal disease market was valued at USD 82.43 billion in 2021. It is projected to reach USD 264.90 billion by 2030, growing at a CAGR of 13.9% during the forecast period (2022–2030).
• Based on treatment segment is further divided into transplant and dialysis. The dialysis segment dominates the market and is expected to hold the largest share during the forecast period.
• The Asia-Pacific will hold the largest end-stage renal disease market share during the forecast period.

Competitive Players

1. B Braun Melsungen AG
2. Baxter International Inc
3. Medtronic PLC
4. Fresenius SE & Co. KGaA
5. Nipro Corporation
6. Asahi Kasei Medical Co.
7. Trivitron Healthcare
8. Guangzhou MeCan Medical Limited
9. JMS North America Corporation
10. NxStage Medical

Recent Developments

• March 2024- Bayer Healthcare, in collaboration with LASCO Pharmaceutical Division, launched finerenone, marketed as Firialta, to treat chronic kidney disease. The medicine prevents inflammation, reduces fibrosis, and decreases the amount of albumin (a protein whose presence in urine indicates kidney disease) in people suffering from renal disease.
• February 2024- the Central Drugs Standard Control Organisation (CDSCO) granted Jardiance (empagliflozin) 10 smg tablets to decrease the risk of long-term decline in patients with end-stage kidney disease, cardiovascular death, and hospitalization in adult individuals with chronic kidney disease (CKD), who are at risk of progression.

Segmentation

1. By Treatment
   1. Transplant
   2. Dialysis
2. By Diagnosis
   1. Blood Test
   2. Urine Test
   3. Imaging Test
   4. Others
3. By End-User
   1. Hospitals and Clinics
   2. Dialysis Centers
   3. Others